Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Use of cyclin-dependent kinase 4/6 inhibitors improved survival outcome of hormone receptor (HR) positive metastatic breast cancer (MBC) patients, including Asian population. However, Asian real-world data of palbociclib is limited. We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib. Materials and MethodsBetween April 2017 to November 2019, 169 HR-positive, human epidermal growth factor-2–negative MBC patients treated with letrozole or fulvestrant plus palbocilib were enrolled from eight institutions. Survival outcome (progression-free survival [PFS]), treatment response and toxicity profiles were analyzed. ResultsMedian age of letrozole plus palbociclib (145 patients, 85.8%) and fulvestrant plus palbociclib (24 patients, 14.2%) was 58 and 53.5 years, with median follow-up duration of 14.63 months (range 0.2 to 33.9 months). Median PFS (mPFS) of letrozole plus palbociclib and fulvestrant plus palbociclib was 25.6 (95% confidence interval [CI], 19.1 to not reached) and 6.37 months (95% CI, 5.33 to not reached), comparable to previous phase 3 trials. In letrozole plus palbociclib arm, luminal A (hazard ratio, 2.86; 95% CI, 1.20 to 6.80; p=0.017) and patients with good performance (Eastern Cooperative Oncology Group 0-1 [hazard ratio, 3.68; 95% CI, 1.70 to 7.96]) showed better mPFS. In fulvestrant plus palbociclib group, chemotherapy naïve patients showed better mPFS (hazard ratio, 12.51, 95% CI, 1.59 to 99.17; p=0.017). The most common grade 3 or 4 adverse event was neutropenia (letrozole 86.3%, fulvestrant 88.3%).ConclusionTo our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice.
Abstract
Purpose Use of cyclin-dependent kinase 4/6 inhibitors improved survival outcome of hormone receptor (HR) positive metastatic breast cancer (MBC) patients, including Asian population. However, Asian real-world data of palbociclib is limited. We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib. Materials and MethodsBetween April 2017 to November 2019, 169 HR-positive, human epidermal growth factor-2–negative MBC patients treated with letrozole or fulvestrant plus palbocilib were enrolled from eight institutions. Survival outcome (progression-free survival [PFS]), treatment response and toxicity profiles were analyzed. ResultsMedian age of letrozole plus palbociclib (145 patients, 85.8%) and fulvestrant plus palbociclib (24 patients, 14.2%) was 58 and 53.5 years, with median follow-up duration of 14.63 months (range 0.2 to 33.9 months). Median PFS (mPFS) of letrozole plus palbociclib and fulvestrant plus palbociclib was 25.6 (95% confidence interval [CI], 19.1 to not reached) and 6.37 months (95% CI, 5.33 to not reached), comparable to previous phase 3 trials. In letrozole plus palbociclib arm, luminal A (hazard ratio, 2.86; 95% CI, 1.20 to 6.80; p=0.017) and patients with good performance (Eastern Cooperative Oncology Group 0-1 [hazard ratio, 3.68; 95% CI, 1.70 to 7.96]) showed better mPFS. In fulvestrant plus palbociclib group, chemotherapy naïve patients showed better mPFS (hazard ratio, 12.51, 95% CI, 1.59 to 99.17; p=0.017). The most common grade 3 or 4 adverse event was neutropenia (letrozole 86.3%, fulvestrant 88.3%).ConclusionTo our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice.
참고문헌 (33)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Breast cancer facts and figures 2019-2020, "American Cancer Society", American Cancer Society, ~ (2019)
- Lin CH, "Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population", J Natl Cancer Inst, 111, pp.1298~1306 (2019)
- Breast cancer facts and figures 2019, "Korean Breast Cancer Society", Korean Breast Cancer Society, ~ (2019)
- Youlden DR, "Incidence and mortality of female breast cancer in the Asia-Pacific region", Cancer Biol Med, 11, pp.101~115 (2014)
- Sung H, "Female breast cancer incidence among Asian and Western populations: more similar than expected", J Natl Cancer Inst, 107, pp.djv107~ (2015)
- Hartman M, "Ability to predict breast cancer in Asian women using a polygenic susceptibility model", Breast Cancer Res Treat, 127, pp.805~812 (2011)
- Kan Z, "Multiomics profiling of younger Asian breast cancers reveals distinctive molecular signatures", Nat Commun, 9, pp.1725~ (2018)
- Finn RS, "Palbociclib and letrozole in advanced breast cancer", N Engl J Med, 375, pp.1925~1936 (2016)
- Hortobagyi GN, "Ribociclib as first-line therapy for HRpositive, advanced breast cancer", N Engl J Med, 375, pp.1738~1748 (2016)
- Slamon DJ, "Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : MONALEESA-3", J Clin Oncol, 36, pp.2465~2472 (2018)
- Sledge GW Jr, "The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2 : a randomized clinical trial", JAMA Oncol, 6, pp.116~124 (2019)
- Goetz MP, "MONARCH 3 : abemaciclib as initial therapy for advanced breast cancer", J Clin Oncol, 35, pp.3638~3646 (2017)
- Cristofanilli M, "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3) : final analysis of the multicentre, double-blind, phase 3 randomised controlled trial", Lancet Oncol, 17, pp.425~439 (2016)
- Im SA, "Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer : results from the phase III, randomized PALOMA-2 study", J Glob Oncol, 5, pp.1~19 (2019)
- Iwata H, "PALOMA-3 : phase III trial of fulvestrant with or without palbo ciclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients", J Glob Oncol, 3, pp.289~303 (2017)
- Im SA, "Overall survival with ribociclib plus endocrine therapy in breast cancer", N Engl J Med, 381, pp.307~316 (2019)
- Yeo W, "Treating HR+", HER2-breast cancer in premenopausal Asian women : Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression, 2019, pp.177, 549~559
- Cardoso F, "4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer(ABC 4)", Ann Oncol, 29, pp.1634~1657 (2018)
- Varella L, "Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy", Breast Cancer Res Treat, 176, pp.429~434 (2019)
- Kish JK, "Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced", metastatic breast cancer treated in community oncology practice in the USA one year post approval, 2018, pp.20, 37~
- Taylor-Stokes G, "Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+", HER2-negative advanced, Breast, pp.2019, 43[DOI]
- Wilkie J, "Progression-free survival for real-world use of palbociclib in hormone receptor-positive metastatic breast cancer", Clin Breast Cancer, 20, pp.33~40 (2020)
- 강상율, "Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry", Journal of Breast Cancer, 23(2), pp.115~128 (2020), 한국유방암학회[DOI]
- Kim HK, "Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women? : result of an institution database from South Korea", BMC Cancer, 19, pp.84~ (2019)
- Kim TY, "Role of endocrine therapy in premenopausal patients with hormone receptor-positive metastatic breast cancer, compared with postmenopausal patients: diachronic analyses from nationwide cohort in Korea (KCSG BR 14-07)", Cancer Res, 76(4 Suppl), pp.P1-09-09~ (2016)
- Spring LM, "Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer : past, present, and future", Lancet, 395, pp.817~827 (2020)
- Huang CY, "Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response", Eur J Cancer, 102, pp.10~22 (2018)
- Chowdhary M, "Safety and efficacy of palbociclib and radiation therapy in patients with metastatic breast cancer : initial results of a novel combination", Adv Radiat Oncol, 4, pp.453~457 (2019)
- Finn RS, "Biomarker analyses of response to cyclin-dependent kinase 4", 6inhibition and endocrine therapy in women with treatmentnaive metastatic breast cancer, 2020, pp.26, 110~121
- Howie LJ, "Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptornegative metastatic breast cancer treated with a CDK4", 6inhibitor and an aromatase inhibitor : an FDA pooled analysis, 2019, pp.37, 3475~3483
- Turner NC, "Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases", Ann Oncol, 29, pp.669~680 (2018)